Trial Profile
Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Tirzepatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 29 Mar 2021 Results published in the Clinical Pharmacokinetics
- 25 Sep 2020 Results assessing impact of Renal impairment on the clinical pharmacokinetics of tirzepatide, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 16 Jun 2020 Results evaluating the pharmacokinetics and tolerability of Tirzepatide in subjects with renal impairment (with or without T2DM) vs. healthy subjects with normal renal function, presented at the 80th Annual Scientific Sessions of the American Diabetes Association